Evan Seigerman
Stock Analyst at BMO Capital
(4.22)
# 371
Out of 5,182 analysts
154
Total ratings
54.9%
Success rate
13.14%
Average return
Main Sectors:
Stocks Rated by Evan Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Maintains: Market Perform | $147 → $140 | $131.60 | +6.38% | 16 | Feb 12, 2026 | |
| BIIB Biogen | Maintains: Market Perform | $165 → $196 | $177.34 | +10.52% | 28 | Feb 9, 2026 | |
| TERN Terns Pharmaceuticals | Maintains: Outperform | $35 → $54 | $52.72 | +2.43% | 3 | Dec 9, 2025 | |
| LLY Eli Lilly and Company | Maintains: Outperform | $1,100 → $1,200 | $935.58 | +28.26% | 10 | Dec 4, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $120 → $130 | $139.71 | -6.95% | 18 | Aug 8, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $557 → $530 | $438.71 | +20.81% | 16 | Aug 5, 2025 | |
| INCY Incyte | Maintains: Underperform | $52 → $60 | $95.93 | -37.45% | 13 | Jul 30, 2025 | |
| IRON Disc Medicine | Maintains: Outperform | $112 → $120 | $65.18 | +84.11% | 6 | May 12, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Market Perform | $57 → $61 | $59.60 | +2.35% | 11 | Nov 12, 2024 | |
| GPCR Structure Therapeutics | Initiates: Outperform | $40 | $53.48 | -25.21% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $40 | $8.41 | +375.62% | 1 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $757 → $788 | $761.85 | +3.43% | 17 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $8 → $2.5 | $4.41 | -43.31% | 2 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $263 → $243 | $347.94 | -30.16% | 6 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $5.00 | +140.00% | 2 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $60 | $28.32 | +111.86% | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $30 | $3.07 | +877.20% | 3 | May 12, 2020 |
Neurocrine Biosciences
Feb 12, 2026
Maintains: Market Perform
Price Target: $147 → $140
Current: $131.60
Upside: +6.38%
Biogen
Feb 9, 2026
Maintains: Market Perform
Price Target: $165 → $196
Current: $177.34
Upside: +10.52%
Terns Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $35 → $54
Current: $52.72
Upside: +2.43%
Eli Lilly and Company
Dec 4, 2025
Maintains: Outperform
Price Target: $1,100 → $1,200
Current: $935.58
Upside: +28.26%
Gilead Sciences
Aug 8, 2025
Maintains: Outperform
Price Target: $120 → $130
Current: $139.71
Upside: -6.95%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Outperform
Price Target: $557 → $530
Current: $438.71
Upside: +20.81%
Incyte
Jul 30, 2025
Maintains: Underperform
Price Target: $52 → $60
Current: $95.93
Upside: -37.45%
Disc Medicine
May 12, 2025
Maintains: Outperform
Price Target: $112 → $120
Current: $65.18
Upside: +84.11%
Bristol-Myers Squibb Company
Nov 12, 2024
Maintains: Market Perform
Price Target: $57 → $61
Current: $59.60
Upside: +2.35%
Structure Therapeutics
Feb 28, 2023
Initiates: Outperform
Price Target: $40
Current: $53.48
Upside: -25.21%
Oct 14, 2022
Maintains: Outperform
Price Target: $30 → $40
Current: $8.41
Upside: +375.62%
Aug 4, 2022
Maintains: Outperform
Price Target: $757 → $788
Current: $761.85
Upside: +3.43%
Aug 2, 2022
Downgrades: Market Perform
Price Target: $8 → $2.5
Current: $4.41
Upside: -43.31%
Apr 28, 2022
Maintains: Market Perform
Price Target: $263 → $243
Current: $347.94
Upside: -30.16%
Mar 31, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $5.00
Upside: +140.00%
Nov 19, 2021
Initiates: Outperform
Price Target: $60
Current: $28.32
Upside: +111.86%
May 12, 2020
Maintains: Outperform
Price Target: $13 → $30
Current: $3.07
Upside: +877.20%